ViroStatics srl The company was founded in 2005 by the Research Institute for Genetic and Human Therapy, USA (RIGHT) and Società Finanziaria Regione Sardegna, Italy (SFIRS). The Company has its registered office in Sassari, headquarters and laboratories in Alghero, Sardinia (Italy) and operational offices in Princeton, New Jersey (USA). Our focus is on the development of novel therapeutics in the fields of chronic, life-threatening infections that both improve immune function and suppress pathogen replication. The Company's lead candidates are novel antiviral/immune protective compounds for the treatment of HIV/AIDS. It has developed an innovative core platform to achieve its goal: a new drug class now known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs). Our company has successfully established the Proof of Concept in man for this new class of antiviral/immune protective agents that it has pioneered using its two-drug first-generation AV-HALT, VS411.